KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib (Q44893639)

From Wikidata

Jump to navigation Jump to search

scientific article published on August 16, 2011

Language	Label	Description	Also known as
English	KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib	scientific article published on August 16, 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

author name string

D. Marin

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21844874

9 December 2024

I. H. Gabriel

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21844874

9 December 2024

S. Ahmad

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21844874

9 December 2024

L. Foroni

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21844874

9 December 2024

H. de Lavallade

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21844874

9 December 2024

R. Clark

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21844874

9 December 2024

S. O'Brien

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21844874

9 December 2024

R. Sergeant

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21844874

9 December 2024

C. Hedgley

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21844874

9 December 2024

D. Milojkovic

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21844874

9 December 2024

J. S. Khorashad

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21844874

9 December 2024

M. Bua

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21844874

9 December 2024

A. Alsuliman

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21844874

9 December 2024

A. Khoder

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21844874

9 December 2024

K. Stringaris

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21844874

9 December 2024

N. Cooper

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21844874

9 December 2024

J. Davis

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21844874

9 December 2024

J. M. Goldman

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21844874

9 December 2024

J. F. Apperley

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21844874

9 December 2024

K. Rezvani

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21844874

9 December 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21844874

9 December 2024

publication date

16 August 2011

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

full work available at URL

https://www.nature.com/articles/leu2011180.pdf

Portable Document Format

1 reference

10.1038/LEU.2011.180

https://api.crossref.org/works/10.1038/LEU.2011.180

9 December 2024

https://www.nature.com/articles/leu2011180

1 reference

10.1038/LEU.2011.180

https://api.crossref.org/works/10.1038/LEU.2011.180

9 December 2024

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

296-302

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

21 January 2018

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

21 January 2018

Graft-versus-leukemia reactions in allogeneic chimeras

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

21 January 2018

Human natural killer cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

21 January 2018

NK cell recognition

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

21 January 2018

Natural killer cell signaling pathways

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

21 January 2018

Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

21 January 2018

Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

21 January 2018

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

21 January 2018

The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

21 January 2018

Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

21 January 2018

Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

21 January 2018

The decreased susceptibility of Bcr/Abl targets to NK cell-mediated lysis in response to imatinib mesylate involves modulation of NKG2D ligands, GM1 expression, and synapse formation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

21 January 2018

Response definitions and European Leukemianet Management recommendations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

21 January 2018

Diversity of killer cell immunoglobulin-like receptor genes in Pacific Islands populations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

21 January 2018

The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

21 January 2018

Methods for assessing gene content diversity of KIR with examples from a global set of populations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

21 January 2018

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

21 January 2018

Use of natural killer cells as immunotherapy for leukaemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

21 January 2018

Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

21 January 2018

Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

21 January 2018

Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

21 January 2018

Role of amino acid position 70 in the binding affinity of p50.1 and p58.1 receptors for HLA-Cw4 molecules.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

21 January 2018

Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

21 January 2018

Murine cytomegalovirus is regulated by a discrete subset of natural killer cells reactive with monoclonal antibody to Ly49H.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

21 January 2018

Recognition of a virus-encoded ligand by a natural killer cell activation receptor

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

21 January 2018

Immunology. A pathogen receptor on natural killer cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

21 January 2018

The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

21 January 2018

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

21 January 2018

Soluble HLA-I-mediated secretion of TGF-beta1 by human NK cells and consequent down-regulation of anti-tumor cytolytic activity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

21 January 2018

Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

21 January 2018

TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

21 January 2018

Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

7 January 2021

based on heuristic

inferred from DOI database lookup

Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

7 January 2021

based on heuristic

inferred from DOI database lookup

Definition of the accelerated phase of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

7 January 2021

based on heuristic

inferred from DOI database lookup

Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

7 January 2021

based on heuristic

inferred from DOI database lookup

Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.180

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2011.180

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44893639&oldid=2285351427"